Stock Scorecard
Stock Summary for Arcus Biosciences Inc (RCUS) - $18.88 as of 3/28/2024 9:59:57 PM EST
Total Score
9 out of 29
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for RCUS
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for RCUS
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for RCUS
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 |
Bonus Criteria for RCUS
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Latest News for for RCUS
Financial Details for RCUS
Company Overview |
|
---|---|
Ticker | RCUS |
Company Name | Arcus Biosciences Inc |
Country | USA |
Description | Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 12/31/2023 |
Next Earnings Date | 5/7/2024 |
Stock Price History |
|
Last Day Price | 18.88 |
Last Day Price Updated | 3/28/2024 9:59:57 PM EST |
Last Day Volume | 744,390 |
Average Daily Volume | 946,963 |
52-Week High | 25.47 |
52-Week Low | 12.95 |
Last Price to 52 Week Low | 45.79% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 100.07 |
Sector PE | 60.76 |
5-Year Average PE | 13.54 |
Free Cash Flow Ratio | 2.26 |
Industry Free Cash Flow Ratio | 12.70 |
Sector Free Cash Flow Ratio | 31.04 |
Current Ratio Most Recent Quarter | 4.52 |
Total Cash Per Share | 8.35 |
Book Value Per Share Most Recent Quarter | 6.12 |
Price to Book Ratio | 3.24 |
Industry Price to Book Ratio | 5.57 |
Sector Price to Book Ratio | 21.66 |
Price to Sales Ratio Twelve Trailing Months | 12.79 |
Industry Price to Sales Ratio Twelve Trailing Months | 13.94 |
Sector Price to Sales Ratio Twelve Trailing Months | 8.77 |
Share Statistics |
|
Total Shares Outstanding | 90,865,000 |
Market Capitalization | 1,715,531,200 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Dividend Aristocrat? | False |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -14.98% |
Reported EPS 12 Trailing Months | -4.15 |
Reported EPS Past Year | -4.15 |
Reported EPS Prior Year | -3.72 |
Net Income Twelve Trailing Months | -307,000,000 |
Net Income Past Year | -307,000,000 |
Net Income Prior Year | -267,000,000 |
Quarterly Revenue Growth YOY | -8.80% |
5-Year Revenue Growth | 69.54% |
Balance Sheet |
|
Total Cash Most Recent Quarter | 759,000,000 |
Total Cash Past Year | 759,000,000 |
Total Cash Prior Year | 1,009,000,000 |
Net Cash Position Most Recent Quarter | 759,000,000 |
Net Cash Position Past Year | 759,000,000 |
Long Term Debt Past Year | 0 |
Long Term Debt Prior Year | 0 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 462,000,000 |
Total Stockholder Equity Prior Year | 657,000,000 |
Total Stockholder Equity Most Recent Quarter | 462,000,000 |
Options |
|
Put/Call Ratio | 0.30 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | 0.12 |
MACD Signal | 0.39 |
20-Day Bollinger Lower Band | 13.20 |
20-Day Bollinger Middle Band | 16.77 |
20-Day Bollinger Upper Band | 20.34 |
Beta | 0.81 |
RSI | 46.54 |
50-Day SMA | 18.23 |
200-Day SMA | 25.81 |
System |
|
Modified | 3/27/2024 5:21:10 AM EST |